Reduced AICD was also confirmed by the prolonged survival of the TCR/HLA-I/Fasneg CAR T cells in the peripheral blood of the CAR19 T cell-treated Nalm6-bearing mice (Figure 4E), which in turn enhanced the tumor control efficacy of the CD19 CAR T cells (Figure 4F, 4G). Here, CD19 is linked to neoplasm.